1. Date of download: 6/9/2016 From: Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus– Infected Patients Without Previous Psychiatric Disease: A Randomized Trial Ann Intern Med. 2012;157(2):94-103. doi:10.7326/0003-4819-157-2-201207170-00006 Study flow diagram. Most patients who discontinued treatment early withdrew for reasons associated with the antiviral therapy (e.g., nonresponse). HCV = hepatitis C virus; PEG-IFN-α2a = pegylated interferon-α2a. * During the 2-wk pretreatment period, antiviral therapy was not yet started. † This patient died of causes unrelated to the study. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

2. Date of download: 6/9/2016 From: Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus– Infected Patients Without Previous Psychiatric Disease: A Randomized Trial Ann Intern Med. 2012;157(2):94-103. doi:10.7326/0003-4819-157-2-201207170-00006 Cumulative Kaplan–Meier estimates of the time to first episode of depression during antiviral treatment. More patients in the escitalopram pretreatment group remained depression-free (defined as a MADRS score ≥13) than those in the placebo group (hazard ratio, 0.43 [95% CI, 0.26 to 0.70]; log-rank test P < 0.001). MADRS = Montgomery–Asberg Depression Rating Scale. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

3. Date of download: 6/9/2016 From: Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus– Infected Patients Without Previous Psychiatric Disease: A Randomized Trial Ann Intern Med. 2012;157(2):94-103. doi:10.7326/0003-4819-157-2-201207170-00006 Montgomery–Asberg Depression Rating Scale scores during hepatitis C virus therapy. Significant group differences were seen at weeks 12 (P = 0.004), 24 (P = 0.002), and 48 (P = 0.001, genotypes 1 and 4). * Only genotypes 1 and 4. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

4. Date of download: 6/9/2016 From: Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus– Infected Patients Without Previous Psychiatric Disease: A Randomized Trial Ann Intern Med. 2012;157(2):94-103. doi:10.7326/0003-4819-157-2-201207170-00006 General health status assessed by using the SF-36. For all subscales except for “health change,” a high score indicates a better state of health (0 = worst possible health state; 100 = best possible health state). For “health change,” lower scores indicate fewer negative health changes. Significant group differences during the first 24 wk of the trial were seen for the mental health summary score (P = 0.002) and within the domains of general health perception (P = 0.037), social functioning (P = 0.035), and mental health (P < 0.001). At 48 wk, additional group differences were found in patients with genotype 1 or 4 for general health perception (P = 0.047), mental health (P = 0.003), health change (P = 0.003), role limitations due to emotional problems (P = 0.003), social functioning (P = 0.025), and mental summary score (P = 0.003). SF-36 = Short Form-36. * Only genotypes 1 and 4. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians